Aller au contenu principal
Accès ouvert déclaré 2026 article

Persistent Airflow Limitation in Asthma: Clinical Characteristics, Risk Factors, and Long−term Outcomes from a Multicenter Cohort Study

0Citations signalées, ce qui n’est pas une note de qualité
12Institutions déclarées
3Pays d’affiliation déclarés

Rattachement africain : kr, us, ie. Niveau de preuve : code pays fourni par la source.

Le résumé fourni par la source

Background: Persistent airflow limitation (PAL) is an increasingly recognized asthma phenotype, but its prevalence, determinants, and prognostic significance in real-world settings remain unclear. This study evaluated the clinical characteristics and long-term outcomes associated with PAL and its severity in asthma. Methods: Multicenter analysis of combined retrospective and prospective cohorts in South Korea. PAL was defined as post-bronchodilator FEV 1 /FVC < 0.70; severity was graded by STaging of Airflow obstruction by Ratio classification (STAR stage). Outcomes included subsequent exacerbations and longitudinal lung function change. Results: Among 849 patients with asthma, 640 (75.4%) had PAL. PAL was associated with older age, male sex, lower body mass index, higher smoking intensity, lower FEV 1 , history of tuberculosis, and less frequent allergic rhinitis. Optimal predictors of PAL were FEV 1 ≤ 83.7% predicted, age ≥ 63.5 years, and smoking intensity ≥ 9.5 pack-years. During follow-up, severe exacerbations occurred more frequently in the PAL group (13.0% vs 5.7%) with a 1.8-fold higher incidence (IRR 1.77, 95% CI 1.13– 2.79). Risk increased with PAL severity, particularly at STAR stage 4 vs stage 0 (aHR 3.32, 95% CI 1.60– 6.89). Longitudinally, annual FEV 1 decline was slower in PAL than in non-PAL (− 28.1 vs − 42.5 mL/year, P = 0.028), but within PAL, STAR stage 4 showed relatively faster declines in both FEV 1 and FVC. Conclusion: PAL and its severity independently predict the risk of severe exacerbations and progressive lung function decline in asthma, underscoring PAL as a key marker of disease progression and a potential target for early intervention. Keywords: asthma, persistent airflow limitation, exacerbation, lung function

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.

Le contrôle bibliographique ouvert

DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.

Titre Crossref
Persistent Airflow Limitation in Asthma: Clinical Characteristics, Risk Factors, and Long−term Outcomes from a Multicenter Cohort Study
Date Crossref
01/07/2026
Éditeur
Informa UK Limited
Type
journal-article

Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.

Les institutions déclarées

Une affiliation ne permet pas de déduire la nationalité d’un auteur.

Les sujets associés

Asthma and respiratory diseasesDelphi Technique in ResearchChronic Obstructive Pulmonary Disease (COPD) Research

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.